The invention relates to poly(propylene imine) glycodendrimers, abbreviated as GD-PPI, wherein GD is a dendrimer coated with a sugar selected from a group comprising monosaccharides, disaccharides and trisaccharides, and PPI is a poly(propylene imine) dendrimer selected from a group of third, fourth and fifth generation dendrimers with a level of coating (surface modification) with a selected sugar within a range above 5 to about 100%, for therapeutic use in neoplastic diseases associated with chromosomal and/or genetic aberrations typical of chronic B cell lymphoproliferative diseases. The above group of compounds includes novel poly(propylene imine) glycodendrimers, abbreviated as GD-PPI, wherein GD is a dendrimer coated with lactose (disaccharide) or mannose (monosaccharide), and PPI is as defined above. In addition, the poly(propylene imine) glycodendrimers, abbreviated as GD-PPI, wherein GD is a dendrimer coated with maltotriose (trisaccharide) with a level of coating within the range above 5 to about 100%, except the values from 35% to 45% and from 80% to 95% which are being excluded, and PPI is as defined above, are novel. Selected compounds from the group of glycodendrimers defined above are intended for the therapeutic use in proliferative neoplastic blood diseases with an impaired apoptosis mechanism. The invention relates also to pharmaceutical compositions comprising the afore-mentioned compounds as therapeutically active substances. The aforementioned compounds are used for the manufacture of medicaments against the indicated medical conditions and in methods of treatment of those medical conditions.Linvention concerne des glycodendrimères de poly(propylène-imine), ou GD-PPI, GD étant un dendrimère recouvert dun sucre choisi dans un groupe comprenant les monosaccharides, les disaccharides et les trisaccharides, et le dendrimère de PPI étant un dendrimère de poly(propylène-imine) choisi dans un groupe de dendrimères de troisième, quatrième et cinquième g
